DEPOMED INC
10-Q, EX-27.1, 2000-11-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: DEPOMED INC, 10-Q, 2000-11-14
Next: COLUMBUS MCKINNON CORP, 10-Q, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM DEPOMED, INC.'S
BALANCE SHEET (UNAUDITED) FOR SEPTEMBER 30, 2000 AND STATEMENT OF INCOME
(UNAUDITED) FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2000 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-2000
<PERIOD-START>                             JUL-01-2000             JAN-01-2000
<PERIOD-END>                               SEP-30-2000             SEP-30-2000
<CASH>                                       2,976,761               2,976,761
<SECURITIES>                                 1,500,540               1,500,540
<RECEIVABLES>                                  381,926                 381,926
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                                57,747                  57,747
<PP&E>                                       1,643,280               1,643,280
<DEPRECIATION>                               (658,614)               (658,614)
<TOTAL-ASSETS>                               6,195,396               6,195,396
<CURRENT-LIABILITIES>                        1,712,115               1,712,115
<BONDS>                                              0                       0
                                0                       0
                                 12,603,000              12,603,000
<COMMON>                                    19,780,864              19,780,864
<OTHER-SE>                                           0                       0
<TOTAL-LIABILITY-AND-EQUITY>                 6,195,396               6,195,396
<SALES>                                              0                       0
<TOTAL-REVENUES>                               381,926                 381,926
<CGS>                                                0                       0
<TOTAL-COSTS>                                        0                       0
<OTHER-EXPENSES>                             2,267,829               2,267,282
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                              18,675                 207,137
<INCOME-PRETAX>                            (2,378,872)             (6,205,538)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                        (2,378,872)             (6,205,538)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (2,378,872)             (6,205,538)
<EPS-BASIC>                                     (0.36)                  (0.95)
<EPS-DILUTED>                                   (0.36)                  (0.95)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission